Cancer-testis antigen SLLP1 represents a promising target for the immunotherapy of multiple myeloma

Table 1 Patient characteristics and association with SLLP1 expression

Characteristics	SLLP1-positive	SLLP1-negative	Sig.
Total (N = 177)	72 (40.7)	105 (59.3)
Age (years)
≤60	45 (36.6)	78 (63.4)	0.094
>60	27 (50.0)	27 (50.0)
Sex
Male	46 (41.1)	66 (58.9)	0.889
Female	26 (40.0)	39 (60.0)
Initial stage
I	10 (38.5)	16 (61.5)	0.928
II	10 (38.5)	16 (61.5)
III	52 (41.6)	73 (58.4)
Heavy chain isotype
IgG	41 (40.2)	61 (59.8)	0.246
IgA	22 (47.8)	24 (52.2)
IgM	1 (100.0)	0 (0.0)
Light chain	8 (28.6)	20 (71.4)
Light chain isotype
Kappa	43 (37.7)	71 (62.3)	0.281
Lambda	29 (46.0)	34 (54.0)
Cytogenetics
Normal karyotype	25 (43.1)	33 (56.9)	0.345
Del13q14	31 (58.5)	22 (41.5)	0.069
Del17p13	9 (64.3)	5 (35.7)	0.192
t(4;14)	9 (81.8)	2 (18.2)	0.018
Other	13 (38.2)	2 (61.8)	0.198

A total of 177 patients with MM were classified according to the clinical features of their disease. Information on cytogenetics (N = 136) was available for fewer patients. A patient was considered SLLP1-positive if at least one of all samples collected per patient evidenced SLLP1 RNA expression. Importantly, median follow-up time was not significantly different between SLLP1-postive and -negative patients (data not shown). P values as calculated by Chi-square test are indicated in the column on the far right.

ISSN: 1479-5876